DelfaGLP-1 Atlas

Lead sponsor

Brigham and Women's Hospital

29 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 1, 2026.

29

Trials led

12

Active

4,013,110

Total enrollment

42

Sites

Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.

Portfolio

How this sponsor's trials break down

Trials by phase

Phase 2
3
Phase 4
2
Not applicable
24

Trials by status

Not yet recruiting
1
Recruiting
4
Active, not recruiting
7
Completed
14
Unknown
3

Trials led

TIRZSEMA-CVOTBMI ≥25not applicableCompleted887,132
CER-4-T2D—not applicableActive, not recruiting781,430
Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 InhibitorsAge ≥65not applicableCompleted742,670
BESTMEDHbA1c 7-11%not applicableUnknown550,000
Replication of the LEADER Diabetes Trial in Healthcare Claims—not applicableCompleted168,690
Emulation of the SUSTAIN6 Diabetes Trial Using Healthcare ClaimseGFR ≤60not applicableCompleted158,310
Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular RiskBMI ≥25not applicableActive, not recruiting120,000
Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes.BMI ≥25not applicableActive, not recruiting100,000
Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 DiabetesEstablished ASCVDnot applicableCompleted70,000
INTERCEPTBMI ≥25not applicableActive, not recruiting60,000
DUP-STEP-HFpEFBMI ≥30not applicableCompleted58,387
Comparative Effectiveness of Tirzepatide Versus Sitagliptin in Individuals at Cardiovascular Risk (TIRZSITA-CVOT)BMI ≥25not applicableCompleted49,065
DUP-SURPASSBMI ≥25not applicableCompleted44,671
Emulation of the SOUL Diabetes Trial in Healthcare ClaimseGFR ≤60not applicableCompleted43,650
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.BMI ≥23not applicableActive, not recruiting30,000
DUP-TIRZSEMABMI ≥27not applicableCompleted28,118
Emulating the PIONEER6 Diabetes Trial Using Healthcare ClaimseGFR ≤60not applicableCompleted26,126
Comparative Effectiveness of Tirzepatide vs Semaglutide in Participants With Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction—not applicableActive, not recruiting26,000
Comparative Effectiveness of Oral Semaglutide vs Sitagliptin Among Individuals With Heart Failure With Preserved Ejection Fraction (STEP-HFpEF DM ORAL)BMI ≥27not applicableActive, not recruiting25,664
Cardiovascular Outcomes and HbA1c Among Patients With Type 2 Diabetes Newly Initiating GLP1RAs vs Basal Insulin—not applicableUnknown20,000
DUP-SUMMITBMI ≥27not applicableCompleted11,265
PRECIDENTDEstablished ASCVD/CKDPh 4Recruiting6,000
Replication of the LEAD-2 Diabetes Trial in Healthcare Claims Data—not applicableCompleted3,474
Prediction of the SEPRA Diabetes Trial in Healthcare Claims Data—not applicableCompleted2,316
SHOREBMI ≤25Ph 2Recruiting46
LIROHBMI ≥30Ph 4Unknown40
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist TreatmentBMI ≥30not applicableRecruiting30
STREAM—Ph 2Recruiting20
Tirzepatide for the Treatment of Cannabis Use Disorder—Ph 2Not yet recruiting6